---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000137"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T14:22:15.132278+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva FY2023 revenue $15.8B, Non-GAAP EPS $2.56; AUSTEDO $1.2B; 2024 guidance issued; revises prior results

## Summary
- Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.
- Non-GAAP diluted EPS $2.56 (vs $2.52 in 2022); GAAP net loss $(0.50) per share.
- AUSTEDO annual revenue exceeded $1.2B (+28%); AJOVY $435M (+16%).
- 2024 outlook: revenue $15.7-$16.3B, Non-GAAP EPS $2.20-$2.50, free cash flow $1.7-$2.0B.
- Revision: $132M contingent consideration understatement; material weakness in internal controls identified.

## SEC filing metadata
- accession: 0001157523-24-000137
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/a53889897.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000137
- JSON: https://secwatch.observer/filing/0001157523-24-000137.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000137.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported 2024 results: revenue $15.7 - $16.3 billion, EPS $2.20 - $2.50. Guidance initiated.
  - Period: 2024
  - Revenue: $15.7 - $16.3 billion
  - EPS: $2.20 - $2.50
  - Guidance: initiated
  - Result: guidance update
  source text: 2024 Business Outlook : Revenues of $15.7 - $16.3 billion Non-GAAP operating income of $4.0-$4.5 billion Adjusted EBITDA of $4.5 - $5.0 billion Non-GAAP diluted EPS of $2.20 - $2.50 Free cash flow of $1.7 - $2.0 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended December 31, 2023 results: revenue $4.5 billion, EPS $0.41. Guidance initiated.
  - Period: the quarter ended December 31, 2023
  - Revenue: $4.5 billion
  - EPS: $0.41
  - Guidance: initiated
  - Result: reported results
  source text: Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the fiscal year ended December 31, 2023 results: revenue $15.8 billion, EPS $(0.50). Guidance initiated.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $15.8 billion
  - EPS: $(0.50)
  - Guidance: initiated
  - Result: reported results
  source text: Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.